Saravanan Subramaniam
Christoph Reinhardt
Paresh P. Kulkarni
Luca Spiezia- 1Pulmonary Center, Department of Medicine, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, United States
- 2Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
- 3German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany
- 4Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
- 5Thrombosis and Hemorrhagic Diseases Unit Medicine, Padova University Hospital, Padova, Italy
Editorial on the Research Topic
COVID-19 and thrombo-inflammatory responses
Introduction
The Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) presents with varying clinical symptoms between individuals. Severe COVID-19 causes pneumonia, acute respiratory distress syndrome (ARDS), cytokine storm, and multi-organ failure (1, 2). Despite the end of the epidemic, COVID-19 is still prevalent, transitioning from a lethal phase to one in which people can become infected without experiencing major symptoms or being hospitalized. COVID-19 is associated with a significant increase in the risk of venous and arterial thromboembolic events in hospitalized patients (3, 4), which is associated with vascular barrier dysfunction, edema, endotheliitis, thrombosis, and inflammatory cell infiltration. Although multiple organ failure in COVID-19 is caused by several mechanisms (5, 6), a hypercoagulation state with the development of micro- and macro- circulatory thrombosis plays a prominent role.
This Research Topic is intended to further understanding of COVID-19 and COVID-19-associated thrombo-inflammatory responses. The current issue has 11 articles, most of which are on thrombocytopenia, thromboprophylaxis regimens, Long COVID, and vaccine-induced immune thrombotic thrombocytopenia (VITT). Many of the articles were written from a clinical standpoint to increase insights into COVID-19 pathophysiology in the setting of prothrombotic response.
Platelets and COVID-19
Platelets are well-known for their critical contributions to thrombosis and hemostasis (7). During infection, activated platelets adhere to the sub-endothelium, and their hyperactivity results in thrombus formation, leading to arterial ischemia and even pulmonary embolisms. Acetylcholine is known to reduce platelet activation via α7 nicotinic acetylcholine receptors (α7nAChR) (8–10). Accumulating evidence suggests that stimulated platelets generate choline products, which activate the α7nAChR, resulting in a positive anti-inflammatory and anti-thrombotic impact. In this issue, Jankauskaite et al. reviewed platelet functions in COVID-19-associated thrombosis and α7nAChR-mediated anti-inflammatory pathway. Nevertheless, in vivo studies are required to validate the significance of α7nAChR in platelet function and whether it might be a possible therapeutic target for reducing platelet hyperreactivity during infection, particularly in COVID-19.
Transforming growth factor-β1 (TGF-β1) functions in maintaining a healthy microvasculature by regulating inflammation, clotting, and wound healing. Platelets are the most abundant source of human TGF-β1 (40–100 times more than other cells), which is stored in its latent form in platelet granules (11). In this issue, Arguinchona et al. have summarized, with caveats, the role of TGF-β1 in thrombosis, inflammation, and immune dysregulation in various diseases, including SARS-CoV-2 infection.
Platelet volume indices (PVI), including mean platelet volume (MPV), platelet distribution width (PDW) and platelet-large cell ratio (P-LCR), are considered useful predictors of thrombotic events (12, 13). In the issue, Daniels et al. systematically evaluated the usefulness of PVI as clinical biomarkers for COVID-19 prognosis and as early predictors for severity and mortality in COVID-19. They found that due to the variability in results, it was difficult to conclude whether COVID-19 patients with elevated PVI are more likely to develop severe illness or are at higher risk of mortality.
Platelets are activated during COVID-19 and participate in thrombo-inflammatory responses (14–16). RNA-Seq has indicated both direct and indirect impacts of SARS-CoV-2 infection (e.g., mediators, aberrant antibodies) on the platelet transcriptome of critically ill COVID-19 patients (16). Due to conflicting reports (17, 18), the exact molecular mechanisms behind the direct activation of platelets during SARS-CoV-2 infection remain largely unknown and are likely multifactorial. Cappelletto et al. screened >3,000 FDA/EMA approved drugs and identified Niclosamide and Clofazimine as the most effective at suppressing Spike-induced TMEM16 activation. Spike induced a marked procoagulant phenotype in platelets, by enhancing Ca2+ flux, phosphatidylserine externalization on the platelet outer cell membrane, and thrombin generation which were inhibited by Niclosamide and Clofazimine.
Fibrin and COVID-19
Coagulation results in an insoluble clot of crosslinked fibrin. Fibrin monomers (FM) have been proposed as a diagnostic marker of DIC (19) and a predictor of thrombosis and/or a hypercoagulable state earlier than D-dimer (20). In healthy individuals, FM levels are very low in peripheral blood, often below the detection limit. In this issue, Smadja et al. evaluated the relationship between FM and COVID-19 mortality in hospitalized patients. FM levels >7 μg/ml were used as lower cut-off and were monitored during initial hospitalization to predict COVID-19 outcomes. During the first 9 days of hospitalization 37% of patients had positive FM at least once; these patients had higher in-hospital mortality (p = 0.001), indicating that monitoring fibrin monomers might be a prognostic tool in moderate-to-critically ill COVID-19 patients.
Thrombocytopenia and prophylactic regimens in COVID-19
High-quality evidence from meta-analyses and randomized controlled trials exploring the clinical outcomes of several preventive regimens in critically ill patients has resulted in contradictory findings (21–23). The anticipated benefit of increasing the anticoagulant dosage is still debated. Rychlíčková et al. in a case study, reported that Fondaparinux can be considered a reasonable and affordable anticoagulant, without a high risk of bleeding, in patients on extracorporeal membrane oxygenation (ECMO). Similarly, Alrashed et al. performed a retrospective cohort analysis (811 patient records) on standard, intermediate, and high anticoagulation dosage regimens in critically ill COVID-19 patients. There were no statistically significant differences in overall in-hospital mortality between the standard-dose and the intermediate-dose groups [51 vs. 53.4%; aHR = 1.4 (95% CI: 0.88–2.33)] or standard-dose and high-dose groups [51 vs. 61.1%; aHR = 1.3 (95% CI: 0.83–2.20)]. The intermediate- and high-dose groups experienced the same frequency of major bleeding episodes as the standard dose group. Thus, these findings recommend standard-dose as the preferred regimen for COVID-19-patients.
Long COVID-19
The older the patients, the more likely they are to succumb to COVID-19 due to immunological dysfunction (24) and comorbidities (25), such as obesity. Many cohort and case-control studies have shown high body mass index (BMI) as a risk factor for disease severity and mortality in COVID-19 patients (26). In this issue, Xiang et al. review suggest that the intersection of obesity and Long COVID, and persistent viral presence, long-term inflammation, micro clots, and hypoxia may contribute to the development of persistent symptoms, and that patients with obesity are uniquely susceptible to Long COVID.
Jaeger et al. in their perspective, propose that acute and Long COVID patients may benefit from treatment with Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) apheresis, which has been in clinical use for 37 years. H.E.L.P removes microthrombi without causing bleeding, enhances oxygen supply to the capillaries, lowers cytokine storm, and removes precursors of the procoagulant and fibrinolytic cascade.
Vaccines and thrombosis in COVID-19
Vaccination has been the most promising strategy for combating the COVID-19 pandemic. Antibodies that recognize platelet factor 4 (PF4, also known as CXCL4) bound to platelets caused VITT (27). Cari et al. conducted a meta-analysis of several adenovirus-based vaccinations and their incidence of VITT, non-VITT thrombosis, and arterial events. Although rare, recipients of the Vaxzevria and Jcovden vaccinations had a greater incidence of VITT compared to Comirnaty, implying a link between these occurrences and the adenovirus-based vaccines. The authors hypothesize that the venous and arterial thromboses observed with adenovirus-based vaccines and in absence of thrombocytopenia are due to the combination of at least three triggering factors, all of which may be involved in vascular inflammation and coagulation and suggest that it is independent of anti-PF4 antibodies. Likewise, Jevtic et al. present an update on the clinical diagnosis of VITT and a comprehensive assessment of VITT epidemiology, and similarities and differences between HIT and VITT. According to the review, HIT and VITT antibodies bind to distinct locations on PF4. Furthermore, diagnostic tests established for HIT frequently produce false-negative findings for VITT and should not be employed as a VITT diagnostic test.
Conclusions
In conclusion, this special issue (perspective, case report, research findings, selective reviews, and meta-analysis) highlights the importance of COVID-19 and COVID-19-associated thrombocytopenia, thromboprophylaxis regimens, Long COVID, and VITT. Over the past three years, our understanding of COVID-19-associated prothrombotic mechanism is slowly resolving. COVID-19 severity is heavily influenced by co-morbidities. Accumulating evidence reveals that even after recovery, those who had COVID-19 experience ongoing cardiovascular issues such coagulopathy or bleeding disorders. Researchers are also learning more about how new variants could potentially affect Long COVID. We are still investigating to what extent certain groups are at higher risk, and if different groups of people tend to experience different types of Long COVID complications. Further close monitoring of post-COVID conditions will aid in our understanding of Long COVID and how healthcare providers might treat or support people suffering from these long-term impacts.
Author contributions
SS, CR, PPK, and LS are topic editors of this special issue and contributed to writing and revising of this editorial. SS drafted the editorial. All authors contributed to the article and approved the submitted version.
Acknowledgments
We would like to thank all the authors and reviewers that were involved in this Research Topic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J Mol Histol. (2020) 51:613–28. doi: 10.1007/s10735-020-09915-3
2. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. (2020) 45:100618. doi: 10.1016/j.cpcardiol.2020.100618
3. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. (2020) 192:152–60. doi: 10.1016/j.thromres.2020.05.039
4. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. (2020) 324:799–801. doi: 10.1001/jama.2020.13372
5. Subramaniam S, Kothari H, Bosmann M. Tissue factor in COVID-19-associated coagulopathy. Thromb Res. (2022) 220:35–47. doi: 10.1016/j.thromres.2022.09.025
6. Subramaniam S, Ruf W, Bosmann M. Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019. Br J Pharmacol. (2022) 179(10):2086–99. doi: 10.1111/bph.15587
7. Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, et al. Platelet integrin alphaIIbbeta3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. (2019) 12:26. doi: 10.1186/s13045-019-0709-6
8. Bennett JA, Ture SK, Schmidt RA, Mastrangelo MA, Cameron SJ, Terry LE, et al. Acetylcholine inhibits platelet activation. J Pharmacol Exp Ther. (2019) 369:182–7. doi: 10.1124/jpet.118.253583
9. Schedel A, Thornton S, Schloss P, Kluter H, Bugert P. Human platelets express functional alpha7-nicotinic acetylcholine receptors. Arterioscler Thromb Vasc Biol. (2011) 31:928–34. doi: 10.1161/ATVBAHA.110.218297
10. Slevin M, Iemma RS, Zeinolabediny Y, Liu D, Ferris GR, Caprio V, et al. Acetylcholine inhibits monomeric C-reactive protein induced inflammation, endothelial cell adhesion, and platelet aggregation; A potential therapeutic? Front Immunol. (2018) 9:2124. doi: 10.3389/fimmu.2018.02124
11. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. (1983) 258:7155–60. doi: 10.1016/S0021-9258(18)32345-7
12. Huang HL, Chen CH, Kung CT, Li YC, Sung PH, You HL, et al. Clinical utility of mean platelet volume and immature platelet fraction in acute coronary syndrome. Biomed J. (2019) 42:107–15. doi: 10.1016/j.bj.2018.12.005
13. Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood. (1984) 63:1372–5. doi: 10.1182/blood.V63.6.1372.1372
14. Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ Res. (2020) 127:945–7. doi: 10.1161/CIRCRESAHA.120.317803
15. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CRR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. (2020) 136:1330–41. doi: 10.1182/blood.2020007252
16. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood. (2020) 136:1317–29. doi: 10.1182/blood.2020007214
17. Kusudo E, Murata Y, Kawamoto S, Egi M. Variant-derived SARS-CoV-2 spike protein does not directly cause platelet activation or hypercoagulability. Clin Exp Med. (2023):1–8. doi: 10.1007/s10238-023-01091-4
18. Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res. (2020) 127:1404–18. doi: 10.1161/CIRCRESAHA.120.317703
19. Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M, On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. (2001) 86:1327–30. doi: 10.1055/s-0037-1616068
20. Refaai MA, Riley P, Mardovina T, Bell PD. The clinical significance of fibrin monomers. Thromb Haemost. (2018) 118:1856–66. doi: 10.1055/s-0038-1673684
21. Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, et al. Intermediate-Dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost. (2022) 122:131–41. doi: 10.1055/a-1485-2372
22. Lopes RD, De Barros ESPGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. (2021) 397:2253–63. doi: 10.1016/S0140-6736(21)01203-4
23. Perepu US, Chambers I, Wahab A, Ten Eyck P, Wu C, Dayal S, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. J Thromb Haemost. (2021) 19:2225–34. doi: 10.1111/jth.15450
24. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. (2013) 123:958–65. doi: 10.1172/JCI64096
25. Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nat Med. (2023) 29:334–43. doi: 10.1038/s41591-022-02156-9
26. Yang Y, Wang L, Liu J, Fu S, Zhou L, Wang Y. Obesity or increased body mass index and the risk of severe outcomes in patients with COVID-19: a protocol for systematic review and meta-analysis. Medicine (Baltimore). (2022) 101:e28499. doi: 10.1097/MD.0000000000028499
Keywords: COVID-19, thrombo-inflammation, long covid, VITT, platelets and COVID-19, thrombocytopenia, thromboprophylaxis regimens
Citation: Subramaniam S, Reinhardt C, Kulkarni PP and Spiezia L (2023) Editorial: COVID-19 and thrombo-inflammatory responses. Front. Cardiovasc. Med. 10:1231909. doi: 10.3389/fcvm.2023.1231909
Received: 31 May 2023; Accepted: 6 June 2023;
Published: 15 June 2023.
Edited and Reviewed by: Hugo Ten Cate, Maastricht University Medical Centre, Netherlands
© 2023 Subramaniam, Reinhardt, Kulkarni and Spiezia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Saravanan Subramaniam ssubra@bu.edu